PHBBF (Pharmaron Beijing Co) Short-Term Debt: $174 Mil (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

PHBBF Pharmaron Beijing Co Ltd PHBBF
90 GF Score
Price $1.93
GF Value $1.67
! 9 Warning Signs
View Full Analysis

What is Pharmaron Beijing Co Short-Term Debt?

Pharmaron Beijing Co PHBBF 90 Short-Term Debt is $174 Mil as of Mar. 2026. GuruFocus rates PHBBF with a GF Score™ of 90/100 and a GF Value™ of $1.67. The stock has 9 warning signs investors should review.

Pharmaron Beijing Co's Short-Term Debt for the quarter that ended in Mar. 2026 was $174 Mil.

Pharmaron Beijing Co's quarterly Short-Term Debt increased from Sep. 2025 ($174 Mil) to Dec. 2025 ($180 Mil) but then declined from Dec. 2025 ($180 Mil) to Mar. 2026 ($174 Mil).

Pharmaron Beijing Co's annual Short-Term Debt increased from Dec. 2023 ($81 Mil) to Dec. 2024 ($105 Mil) and increased from Dec. 2024 ($105 Mil) to Dec. 2025 ($180 Mil).

Pharmaron Beijing Co Short-Term Debt Explanation

Short-Term Debt represents the total amount of Long-Term Debt such as bank loans and commercial paper, which is due within one year.

Pharmaron Beijing Co Short-Term Debt Related Terms

Pharmaron Beijing Co Short-Term Debt Historical Data

* Premium members only.

The historical data trend for Pharmaron Beijing Co's Short-Term Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Pharmaron Beijing Co Short-Term Debt Chart

Pharmaron Beijing Co Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Short-Term Debt
Get a 7-Day Free Trial Premium Member Only Premium Member Only 66.22 95.07 80.82 105.07 179.66

Pharmaron Beijing Co Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Short-Term Debt Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 110.24 139.59 173.95 179.66 173.65
PHBBF
90GF Score
Pharmaron Beijing Co Ltd PHBBF
Short-Term Debt is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about Short-Term Debt →
What does a Short-Term Debt of $174 Mil mean?
Pharmaron Beijing Co (PHBBF) has a Short-Term Debt of $174 Mil as of Mar. 2026.
Is Pharmaron Beijing Co's Short-Term Debt too high?
Pharmaron Beijing Co's current Short-Term Debt is $174 Mil. Overall, Pharmaron Beijing Co has a GF Score™ of 90/100, reflecting its overall financial health beyond just this single metric.
How does Pharmaron Beijing Co's Short-Term Debt compare to VRTX and REGN?
Pharmaron Beijing Co's Short-Term Debt of $174 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Short-Term Debt for a Biotechnology company?
A good Short-Term Debt depends on the Biotechnology industry context. However, Short-Term Debt should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Short-Term Debt mean?
A high Short-Term Debt can signal that a stock is expensive relative to its fundamentals. Pharmaron Beijing Co's current Short-Term Debt is $174 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Pharmaron Beijing Co stock overvalued right now?
Pharmaron Beijing Co (PHBBF) has a current Short-Term Debt of $174 Mil. The stock's GF Value™ is $1.67, compared to a current price of $1.93 — trading 15.6% above its estimated fair value. The current Short-Term Debt is $174 Mil. Pharmaron Beijing Co's overall GF Score™ is 90/100 with 9 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Short-Term Debt calculated?
Short-Term Debt is calculated from a company's financial statements. For Pharmaron Beijing Co (PHBBF), the current Short-Term Debt is $174 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Pharmaron Beijing Co (PHBBF) Overvalued in 2026?

Based on GuruFocus' analysis, Pharmaron Beijing Co stock appears to be overvalued. The current stock price of $1.93 is trading 15.6% above its estimated GF Value™ of $1.67.

Key valuation signals for PHBBF:

  • Short-Term Debt: $174 Mil
  • GF Value™: $1.67 vs. price of $1.93 (15.6% above fair value)
  • GF Score™: 90/100 with 9 warning signs

No single metric tells the full story. See the PHBBF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Pharmaron Beijing Co Business Description

Address 6 Tai-He Road, 8th Floor, Block 1, Beijing Economic Technological Development Area, Beijing, CHN, 100176
Pharmaron Beijing Co Ltd is a research and development service company supporting the life science industry. The company offers drug research and development service capabilities, ranging from synthetic, medicinal, and analytical chemistry, biology, DMPK, pharmacology, drug safety assessment, radiochemistry, and isotopically labelled metabolism, chemical and pharmaceutical development to clinical development. Its operating segment includes Laboratory services; CMC (small molecule CDMO) services, Clinical development services, and biologics and CGT services. It generates maximum revenue from the Laboratory services segment.
90GF Score

Get the complete analysis for PHBBF

Short-Term Debt is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$1.93
Price
$1.67
GF Value